SCHEMBL634256

SCHEMBL634256

Cc1cccc2cc(C(=O)O)c(CC(=O)O)nc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.44
KDM4E B2RXH2 4/20 0.42
PDE3B Q13370 1/20 0.42
PDE3A Q14432 1/20 0.42
LMNA P02545 2/20 0.42
HTT P42858 1/20 0.42
ALDH1A1 P00352 3/20 0.42
TDP1 Q9NUW8 1/20 0.42
HPGD P15428 2/20 0.41
HSD17B10 Q99714 1/20 0.41
DHODH Q02127 1/20 0.40
PARP1 P09874 1/20 0.40
PARP2 Q9UGN5 1/20 0.40
POLB P06746 1/20 0.40
MAPT P10636 1/20 0.40
CRHBP P24387 1/20 0.40
GFER P55789 1/20 0.40
CRHR2 Q13324 1/20 0.40
PRNP P04156 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31125298 0.85 PRNP (0.47) SMN1; SMN2KDM4ELMNAALDH1A1TDP1
SCHEMBL29058294 0.81 ALDH1A1 (0.52) SMN1; SMN2KDM4ELMNAHTTALDH1A1
SCHEMBL2804814 0.80 KDM4E (0.45) KDM4EPDE3BPDE3ALMNAHTT
SCHEMBL2312441 0.78 MAPT (0.51) SMN1; SMN2KDM4EHTTPOLBMAPT
SCHEMBL5459806 0.78 ALDH1A1 (0.50) KDM4EPDE3BPDE3ALMNAHTT
SCHEMBL24597666 0.77 MEN1 (0.49) KDM4ELMNAALDH1A1TDP1HPGD
SCHEMBL634174 0.76 KDM4E (0.58) SMN1; SMN2KDM4ELMNAALDH1A1HPGD
SCHEMBL5785101 0.74 KDM4E (0.51) KDM4ELMNAHTTALDH1A1TDP1
SCHEMBL634147 0.73 KDM4E (0.38) KDM4ELMNAHTTALDH1A1HPGD
SCHEMBL7564788 0.73 KDM4E (0.47) KDM4EPDE3BPDE3ALMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1507778-B1 ANTI-TUMOUR POLYCYCLIC CARBOXAMIDES UNIV TROBE (AU) 2012-02-22 EP disclosed
US-20090156630-A1 ANTI-TUMOUR POLYCYCLIC CARBOXAMIDES BAGULEY BRUCE CHARLES 2009-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156630-A1 ANTI-TUMOUR POLYCYCLIC CARBOXAMIDES MKI67, MCL1, CCNI SMN1; SMN2 2755/4885KDM4E 744/4885PDE3B 4049/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.